A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.

A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.

Item

http://www.wikidata.org/entity/Q46483294

Q46483294

about

Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review Biologicals in rheumatoid arthritis: current and future Emerging Therapies for Rheumatoid Arthritis Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis.Future therapeutic targets in rheumatoid arthritis?Gut Microbiota Regulates K/BxN Autoimmune Arthritis through Follicular Helper T but Not Th17 Cells.Pathogenic Transdifferentiation of Th17 Cells Contribute to Perpetuation of Rheumatoid Arthritis during Anti-TNF Treatment.The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases Higher efficacy of anti-IL-6/IL-21 combination therapy compared to monotherapy in the induction phase of Th17-driven experimental arthritis Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling The pathogenic role of angiogenesis in rheumatoid arthritis.Ratio of Circulating IFNγ (+) "Th17 Cells" in Memory Th Cells Is Inversely Correlated with the Titer of Anti-CCP Antibodies in Early-Onset Rheumatoid Arthritis Patients Based on Flow Cytometry Methods of the Human Immunology Project Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials.Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis Mechanistic rationales for targeting interleukin-17A in spondyloarthritis.Mechanisms of tissue damage in arthritis.IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application.New treatments for inflammatory rheumatic disease.Ixekizumab for treatment of psoriasis.The IL-23-IL-17 axis in inflammatory arthritis.Harnessing the Therapeutic Potential of Th17 Cells.Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases Mediators of inflammation and bone remodeling in rheumatic disease.Targeting IL-17 with ixekizumab in patients with psoriasis.Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.Selected cytokine pathways in rheumatoid arthritis.Ixekizumab: First Global Approval.Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Immunopathology alters Th17 cell glucocorticoid sensitivity.Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.The Plasticity of Th17 Cells in the Pathogenesis of Rheumatoid Arthritis Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys.

P2860

Q26768254-2FDF0B58-7386-4AFB-8094-29687440BE59 Q26774874-793A376B-48B9-46F1-AE08-52348CA7B4CC Q26780316-49344825-A00C-4C3D-90A2-A93B03AF1A24 Q28078943-A6E282E9-F683-4ACC-8EB9-BD91D0950BC4 Q33827644-39E1AA12-0290-45F3-9297-A38380D22E4A Q33841419-01CB71BF-A8C6-4093-B1CA-784844D9F8C0 Q35897377-F1FF137E-3689-4BBA-B31F-CDF51E6C6306 Q36167063-FC0A71F3-C645-44EF-83E1-2393E3D32DE6 Q36249305-B8C64832-416B-4768-B53C-1F6ABEBB970D Q36270103-0D78B281-364C-44A3-B19B-7D8FB770C143 Q36898544-A66DD5BF-5A29-4B21-BC0A-F4EBCB5B539E Q36934777-62086EEA-558B-4F66-B62A-D82362A8D392 Q36936735-1404F375-8DD9-478A-9C7E-2E7EC882BE56 Q37258941-80CF3486-FBBC-4BDF-BD60-E42AE38E50F8 Q37460263-7DBC0F6B-D57E-48E5-83B3-7F01BBA1E8AA Q37686009-F8ED8377-2B26-46DB-845B-9D76C9691469 Q38248430-19C5F650-ECCD-4B72-92B0-8A02ADEFD889 Q38255855-09389957-A299-4D57-99D8-8037AF310BAC Q38266252-9BC4ACE2-E264-4A6E-90C7-000A5A12A0B5 Q38369782-DA21BA28-D186-4BB4-B985-3D26DC48D778 Q38439641-0981BDA2-6270-4BE1-88F4-69BEAF0B8620 Q38535119-9B119DD6-0D9F-4FD1-B36B-E516F16B279A Q38543052-B6902D43-063D-4284-AA85-A39DF205AAB1 Q38576851-BFAD2E8E-313D-4BE7-9364-8EC96F081C20 Q38633741-92694337-322B-406A-A755-2EED24339F9F Q38663614-69029369-2652-459D-8CF4-01D4508907F0 Q38664951-3DC3C00D-EBA9-4140-A3FF-4751CE8C3CEA Q38697262-6AD1E69C-CF1C-4611-8B88-02FB63193928 Q38755912-C7C84DFB-AA5B-4831-AFC5-A87EA86702D4 Q38813174-AD170F5E-F9C0-4CCD-9491-1226E69F4DBA Q38815234-D66A05BE-FF6A-4818-B314-0D6F046E63BE Q38879975-77B0D0C9-FB48-4BBE-88A5-222409063FF2 Q38959155-A7C3D9A1-D529-4635-88C9-917F2E9ADE17 Q38961129-53EC92FA-19B8-4A1E-A076-328D1514A482 Q39015080-F41A699F-06E4-4015-8413-1F5E966A22FF Q39215645-74663ABD-2D07-44AD-8B6C-2F0F01896DAF Q39264020-59261812-621C-47CD-B4C0-563E9C25B80F Q39429529-7A8B6E9F-30E9-4908-B527-984AEE1D0C3B Q39796268-4D6FBA9D-1C9B-4531-835D-87F44D69777D Q39966848-CC5B9F13-18AC-4ECD-8464-D41F342CD97F

P2860

A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.

Item

http://www.wikidata.org/entity/Q46483294

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

A phase II randomized study of ...... or necrosis factor inhibitors.

@en

A phase II randomized study of ...... or necrosis factor inhibitors.

@nl

type

Item

label

A phase II randomized study of ...... or necrosis factor inhibitors.

@en

A phase II randomized study of ...... or necrosis factor inhibitors.

@nl

prefLabel

A phase II randomized study of ...... or necrosis factor inhibitors.

@en

A phase II randomized study of ...... or necrosis factor inhibitors.

@nl

P1476

A phase II randomized study of ...... or necrosis factor inhibitors.

@en

P2093

Alberto Berman

http://www.w3.org/2001/XMLSchema#string

Chul-Soo Cho

http://www.w3.org/2001/XMLSchema#string

Daniel Braun

http://www.w3.org/2001/XMLSchema#string

Gregory S Cameron

http://www.w3.org/2001/XMLSchema#string

Li Xie

http://www.w3.org/2001/XMLSchema#string

Ling Jin

http://www.w3.org/2001/XMLSchema#string

Maria Greenwald

http://www.w3.org/2001/XMLSchema#string

Mark C Genovese

http://www.w3.org/2001/XMLSchema#string

Olivier Benichou

http://www.w3.org/2001/XMLSchema#string

Pierre-Yves Berclaz

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

P304

1693-1704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.38617

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24623718

http://www.w3.org/2001/XMLSchema#string

P921

interleukin

antibody

A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.

about

P2860

P2860

A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921